In partnership with
January 19, 2026
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
On Martin Luther King Jr. Day, it is worth remembering that durable change is built through law, process, and the unglamorous work of follow-through. Today’s big theme is convergence risk: Schedule III process pressure, a November 12th hemp definition cliff, and a live circuit split on whether states can preference locals in licensing. We also track the push to delay the federal hemp crackdown, Indiana moving faster than Washington, and Florida’s ballot effort fighting both polling reality and signature litigation at the same time.
Today’s edition is supported by The AI Report. This briefing is also supported by our day job at THC Group and by The Hybrid podcast with former regulators Shawn Collins and Erik Gundersen. We actually put together a calendar this year, so expect regular content…we hope.
⚖️ Federal squeeze point
⏳ Hemp cliff politics
🗳️ Florida ballot math
Keep it lawful, keep it human, keep it moving.
You Don’t Need to Be Technical. Just Informed
AI isn’t optional anymore—but coding isn’t required.
The AI Report gives business leaders the edge with daily insights, use cases, and implementation guides across ops, sales, and strategy.
Trusted by professionals at Google, OpenAI, and Microsoft.
👉 Get the newsletter and make smarter AI decisions.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: Federal cannabis policy is entering a period of forced convergence between three distinct legal tracks. On the rescheduling front, President Trump’s executive order directs the Department of Justice to complete the reclassification of marijuana to Schedule III with maximum speed. While the order seeks an expeditious conclusion, the administrative rulemaking process remains technically stayed following a January 2025 interlocutory appeal regarding the disqualification of the DEA as a proponent.
Simultaneously, the industry is preparing for the implementation of Public Law 119-37. Effective November 12th, the federal definition of hemp shifts to a total THC standard and imposes a rigid 0.4 mg per container limit on intoxicating products. This statutory cliff is coinciding with a fundamental disagreement in the federal courts. The Ninth Circuit’s recent Peridot Tree decision, which held that the dormant commerce clause does not protect federally illegal cannabis markets, stands in direct opposition to the Second Circuit’s Variscite ruling.
💡 Why It Matters: Cannabis markets don’t function like typical consumer products (or medical for that matter). We have known that. In this instance, as has been the case historically, the regulatory timeline will dictate your capital allocation more than actual market demand. The transition to a total THC measurement and the 0.4 mg container cap effectively reclassifies the majority of the existing intoxicating hemp market as Schedule I marijuana overnight. Operators face a binary choice: reformulate their entire SKU catalog to meet de minimis thresholds or successfully navigate a state level cannabis licensing process that can take up to a year to finalize.
The circuit split on the dormant commerce clause adds a layer of geographic risk to these operational decisions. In states under the jurisdiction of the First and Second Circuits, residency based licensing preferences are constitutionally vulnerable. Those same rules remain enforceable in the Ninth Circuit. , this lack of judicial uniformity means a licensing strategy that is legally sound in Washington State could be treated as unconstitutional protectionism in New York. While circuit splits typically end up at the Supreme Court, these justices have shown little appetite to wade into cannabis…yet.
🧠 THC Group Take: Call your members of Congress first. Today.
Not as a gesture, as a business tool. Every mature regulated market does it, and there is a reason it works: lawmakers do not move because a trade association sends a PDF, they move because employers in their districts explain consequences in plain English. Make it concrete. Tell them how many people - voters - you employ, what you pay in wages, where you buy inputs, and what happens to that payroll if the federal hemp cliff doesn’t include a transition plan that distinguishes responsible, age-gated low-dose products from the worst actors. Ask for a specific outcome, not sympathy: more time and a real framework that leans on age gates, testing, labeling, and enforcement that targets fraud and synthetics. Invite them to see your facility. They have plenty to learn and you have nothing to hide.
Then do the unglamorous work that keeps you investable while Washington fights about verbs and dates. Build a SKU file that a skeptical regulator could read in five minutes and understand, covering inputs, conversion steps, total THC basis, packaging, serving design, labeling claims, age controls, and the exact channel path from production to sale. Put a second file next to it for your distribution model, because shipping, delivery, and retail setting are where tightening usually starts.
On rescheduling, plan like a CFO that has seen some shit: assume 280E stays with you until you have a final effective date and IRS guidance you would actually rely on, then treat any tax upside as a later-year variable. On hemp, treat November 12th as a manufacturing and retail transition deadline, because reformulation, packaging redesign, retailer resets, and inventory wind-down take real time and cash. If you’ve built around residency or local preference in the Northeast, I get why. It was how states tried to keep benefits local. I was one of those states, at least for some license types. The risk is that a court may see it as protectionism. You want a backup structure ready before litigation freezes things.
Most operators are trying to do this the right way. This is how you protect that effort: make the calls, build the binder, and keep your business out of the gray.
Fast-moving headlines, flagged for what matters.
Capitol Hill is trying to buy time before a federal hemp cliff becomes a business extinction event. Companion bills would push the hemp THC restrictions back two years and move the effective date to November 2028. Supporters frame it as a planting season fix and a bridge for manufacturers and retailers that built legal businesses under the 2018 rules. Advocates want time to replace a blunt cap with age gates, testing, labeling, and targeted enforcement that isolates bad actors. If the delay fails, companies still face a hard deadline with limited runway to retool products, packaging, and channels. (Indiana Public Media)
Indiana is moving to shut the door on intoxicating hemp through a bill that compresses the timeline and narrows the legal lane. Lawmakers advanced a proposal that would align state law with the federal crackdown and set an earlier July effective date. The bill tracks a 0.4 milligram per container cap, restricts lab-made intoxicating cannabinoids, and creates a narrow lane for low-THC products. It shifts oversight to the Indiana Alcohol and Tobacco Commission through a permit system, adds a 21-plus age gate, and blocks online sales, delivery, and on-site consumption. The next fight is enforcement capacity and cost as the regulated lane shrinks and gray market pressure rises. (Indiana Capital Chronicle)
Cornbread just pulled the plug on its Tennessee lawsuit as the federal hemp clock becomes the bigger threat to plan around. The company voluntarily dismissed its challenge to Tennessee’s hemp rules, ending the case on January 6th. Tennessee’s ABC says it will keep enforcing the framework as written. Cornbread has also been highlighting looming federal language that could make broad swaths of hemp products illegal by November 2026, and that timing risk is now reshaping where companies spend legal and political capital. The operational consequence is more lobbying, more state hedging, and less patience for models that depend on direct-to-consumer shipping. (WBIR)
A South Carolina medical cannabis bill may try to ride federal rescheduling as a built-in launch date, not a talking point. Republican Sen. Tom Davis said President Trump’s push to move marijuana to Schedule III could loosen resistance and he is open to delaying the law’s effective date until rescheduling is completed. The bill would route sales through therapeutic cannabis pharmacies overseen by the state Board of Pharmacy with physician authorization and a tracked supply chain. The choke point remains the House, where prior versions have died even after clearing the Senate. If rescheduling becomes a timing mechanism inside the bill, the debate tightens around program design and patient access instead of preemption theater. (Marijuana Moment)
Florida’s adult-use campaign is trying to clear a sixty percent bar with support sitting in the low fifties. A Florida Chamber poll found 51% of likely voters support legalizing adult use marijuana, a four-year low in the Chamber’s tracking. The survey ran January 2nd through January 10th and sampled 602 likely voters with a four-point margin of error. The weakness matters because the 2024 amendment fell short even after massive spending. The practical consequence is a 2026 effort that has to win both process and persuasion with less room for slippage and more leverage for opponents who can slow the clock. (Florida Politics)
Florida’s adult-use initiative is now litigating its signature math while the deadline stays fixed. The Secretary of State and Smart and Safe Florida both appealed after a Leon County judge issued a split ruling on which petition signatures can be invalidated. The judge rejected the state directive tossing about 42,000 signatures tied to inactive voters and upheld a separate directive tossing nearly 29,000 signatures gathered by out-of-state petitioners. The deadline remains February 1st to reach 880,062 valid signatures, with the state website still showing roughly 675,307. The immediate consequence is legal friction inside the verification pipeline, with ballot placement turning on process discipline as much as persuasion. (CBS News Miami)
Maine’s cannabis market is staring at a ballot risk campaign that is being bankrolled from outside the state. A referendum push to end adult use sales and add new tracking and testing requirements to medical marijuana received a $2 million contribution from SAM Action, an out-of-state 501c4. Filings show it is the only donor listed so far for the committee running the petition drive, with substantial spending already going to signature gathering. The campaign is also drawing criticism over how petitioners describe the measure, with opponents arguing the pitch obscures that adult use would end. Petitioners need 67,682 valid signatures by February 2nd to qualify for the November ballot, putting the market in campaign mode months before voters weigh in. (Portland Press Herald)
Michigan wants a referee it can trust in the testing wars, and it is moving a bill to give the state that authority. Pending legislation would formalize a statewide cannabis reference laboratory designed to standardize and audit private testing. The lab was funded in the Fiscal Year 2024 appropriations and has been in the process of opening, but regulators want explicit authority to possess cannabis given federal illegality. The Cannabis Regulatory Agency says it would curb lab shopping by auditing results and supporting investigations in-house. The practical consequence is stronger leverage on potency inflation and contamination disputes, with a state-run check that can back enforcement without outsourcing evidence. (Michigan Advance)
New York’s Metrc transition is forcing licensees to choose between clean controls and whatever keeps the doors open today. OCM set a hard deadline for retailers to enter inventory in Metrc, and Metrc has been issuing New York-specific guidance on transfers, retail item IDs, sampling, and exception reporting. The word workaround should trigger caution because it often signals a gap between required controls and what teams can execute in real time. If a workaround cannot be documented, trained, and defended in an audit, it becomes a risk multiplier. The practical consequence is more manual controls now and more pressure on OCM to clarify the minimum compliant path that keeps commerce moving. (Stupid Dope)
Massachusetts regulators say they are focused, but the market keeps seeing an agency spending energy on old fights instead of future governance. Beacon Hill is weighing an overhaul of the Cannabis Control Commission as public disputes and internal conflict continue to drag. Operators feel the credibility problem in churn, delays, and an enforcement posture that can read personal instead of predictable. Social consumption, lab integrity, and routine licensing mechanics need forward motion, and that gets harder when internal politics becomes the storyline. The consequence is drift, with businesses paying a real cost for uncertainty while the Legislature argues about the agency’s structure. (WWLP)
Social equity keeps getting funded on paper while the programs that keep licensees alive remain optional. A Cannabis Industry Journal analysis argues states are skipping the operational scaffolding that helps new entrants survive. The piece cites survey data showing only 27.3% of U.S. cannabis businesses report profitability, with non-white-owned operators reporting profitability at roughly half the rate of white-owned businesses. It highlights Colorado incubator BIPOCann as a model pairing modest grants with mentorship and capital readiness work that resembles how investors reduce early-stage failure. The consequence is consolidation hiding in plain sight, with capital and time still deciding who lasts even under an equity banner. (Cannabis Industry Journal)
Alcohol’s political class is watching THC drinks with more than casual interest, and research is giving both sides ammunition. High Times points to a Journal of Psychoactive Drugs paper reporting survey respondents were more likely to substitute cannabis beverages for alcohol and reported fewer weekly drinks and less binge drinking after starting. The authors also flag limitations including self-reported data and the lack of causal proof, which matters for policymakers looking for clean public health conclusions. Even with caveats, substitution narratives become legislative fuel for caps, channel restrictions, and enforcement expansion in hemp THC debates. The consequence is a messaging arms race, with beverage stakeholders forced to prove they can operate like a regulated category with age gates, testing, and labeling. (High Times)
Hemp-derived THC just moved another step into the mainstream by showing up at the concession stand. Pabst Theater Group is selling hemp THC candies at venues through a partnership with Milwaukee retailer Kind Oasis. The menu includes low-dose delta-9 products marketed as a calmer option for live events. This forces real-world compliance questions that states rarely answer cleanly, including age checks, dosing literacy, and staff response when a guest overdoes it. The consequence is predictable: once venues normalize these products, policymakers respond with clearer guardrails or fast bans driven by headline risk. (Urban Milwaukee)
New Jersey is testing how hard it can squeeze the legacy market by putting consumer behavior in the enforcement crosshairs. Senate President Nick Scutari introduced legislation that would make knowingly buying cannabis from an unlicensed seller a disorderly persons offense with potential jail time and fines. A separate bill would create an interstate commerce framework allowing the Governor to authorize cross-border agreements if federal law permits. Together, the posture is clear: tighten the in-state funnel now and position New Jersey for regional scale later. The political consequence is heat, because escalating consumer exposure will land badly in communities that were promised legalization would shrink criminalization. (HeadyNJ)
A New Jersey shore town wants cannabis tax money to do something voters can see and touch: rebuild the beach. Upper Township is moving to allow dispensaries and steer local cannabis tax revenue toward beach and dune restoration in Strathmere. Officials are looking for a durable funding stream after storm damage weakened natural defenses and raised the cost of shoreline protection. The plan concentrates dispensaries near a commercial corridor by the Garden State Parkway interchange to limit neighborhood disruption while capturing traffic. The consequence is a new local bargain, with cannabis dollars increasingly tied to core services and judged on visible results. (NJ101.5)
Delaware is trying to protect end-of-life dignity while giving hospitals and nursing facilities a federal escape hatch. A bill filed January 15th would require health care facilities to allow medical marijuana use on site for terminally ill patients with a valid registry card. It includes clinician off ramps when cannabis would interfere with care or be medically inappropriate. It also allows facilities to prohibit use if a federal agency takes enforcement action or issues guidance barring cannabis in health care settings. The operational consequence is policy and staff training work on storage, administration, impairment observation, and family involvement. (CoastTV)
Alabama’s hemp fight is back on the table, and the repeal push is already organizing its own show of force. The Alabama Cannabis Coalition says it will campaign to repeal the 2025 law that tightened rules on hemp and CBD products. The group is framing repeal around consumer access, free markets, and protecting businesses squeezed by the new regime, and it is calling supporters to the State Capitol on January 27th. The effort lands while Alabama’s medical rollout keeps crawling under litigation and administrative strain, which leaves lawmakers juggling two cannabis problems at once. The consequence is renewed bargaining over who gets a legal lane, who gets regulated out, and how hard the state wants to press gray market enforcement. (Alabama Political Reporter)
From the hearing room to the comment section — we’re watching it all.
🏈 Some NFL players are talking more openly about using psychedelics for pain, recovery, and mental health, even while the league’s formal rules lag behind the reality of locker room experimentation. The public health tension is the point: athletes are self-medicating in a high-risk environment where quality control, dosing, and support vary wildly. State reform is moving faster than employer policy, and this is the kind of cultural disclosure that eventually forces governance to catch up. (High Times)
🌍 American oversupply is showing up in a place with no legal adult-use market. Irish reporting says cheap cannabis from the US, Canada, and Thailand is increasingly feeding Ireland’s illicit supply through freight and suitcase mules, undercutting local grow-house economics. (Irish Times)